Drug Development

David Lin, Ph. D., is with the Biologics Consulting Group.

Articles

Almost half of pharmaceutical industry profits continue to come from biopharmaceuticals.

Trends Affecting Biopharmaceutical Manufacturing

Jill Wechsler is Pharmaceutical Technology's Washington Editor, jillwechsler7@gmail.com.

A new program will test the safety and suitability of new inactive ingredients to encourage the accelerated adoption of FDA-accepted excipients in drug development.

FDA Moves to Advance Innovative Excipients

AstraZeneca will establish an API manufacturing facility near Dublin, Ireland.

AstraZeneca to Invest $360 Million in Advanced Manufacturing Facility in Ireland

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Consistency, robustness, and understanding of the API and controlled-release excipients are essential for successful drug dosing.

On Time Delivery: Challenges of Controlled-Release Formulations

Sunday Ndiana-Abasi is an intern pharmacist at the Department of Pharmaceutical Technology and Raw Materials Development in the National Institute for Pharmaceutical Research and Development in Nigeria.

Marlene Ekpo is a youth corp pharmacist and research assistant at the Centre for Nanomedicine and Biophysical Drug Delivery, National Institute for Pharmaceutical Research and Development, and a postgraduate student at the School of International Education, Southern Medical University, Guangzhou, Guangdong, China.

Martins O. Emeje, martinsemeje@yahoo.com, is a professor at the Department of Pharmaceutical Technology and Raw Materials Development and director of the Centre for Nanomedicine and Biophysical Drug Delivery, National Institute for Pharmaceutical Research and Development.

The potential for okra gum as a polymer candidate for new oral drug formulations was evaluated.

Evaluating Okra Gum in a Floating Tablet Formulation as a Novel Drug Delivery System

The European Commission has granted marketing authorization to Incyte and MorphoSys for Minjuvi (tafasitamab) in combination therapy with lenalidomide to treat relapsed or refractory DLBCL.

Incyte and MorphoSys Receive EC Approval for Minjuvi in Combination Therapy for Lymphoma

SpringWorks Therapeutics and the Dana-Farber Cancer Institute will conduct further research into the therapeutic potential of combination therapy with nirogacestat and anti-BCMA agents for multiple myeloma.

SpringWorks Therapeutics and Dana-Farber Team Up to Further Evaluate Potential Multiple Myeloma Treatment

Aadi Bioscience has closed its previously announced merger with Aerpio Pharmaceuticals and a concurrent $155-million PIPE investment.

Aadi Bioscience and Aerpio Pharmaceuticals Close Merger and $155 Million Private Placement

NGM Biopharmaceuticals has disclosed a fourth antibody drug candidate, NGM831, for development into an oncology therapeutic.

NGM Bio Pinpoints Fourth Antibody Drug Candidate for Oncology Therapy Development

Pfizer’s proposed $2.26-billion acquisition of Trillium Therapeutics will add next-generation hematology-targeted immuno-therapeutics to its oncology pipeline.

APIs and Excipients